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Background: Underlying causes of adrenal insufficiency include congenital adrenal
hyperplasia (CAH) and autoimmune adrenocortical destruction leading to autoimmune
Addison’s disease (AAD). Here, we report a patient with a homozygous stop-gain
mutation in 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2), in addition to impaired
steroidogenesis due to AAD.
Case Report: Whole exome sequencing revealed an extremely rare homozygous
nonsense mutation in exon 2 of the HSD3B2 gene, leading to a premature stop
codon (NM_000198.3: c.15C>A, p.Cys5Ter) in a patient with AAD and premature
ovarian insufficiency. Scrutiny of old medical records revealed that the patient was
initially diagnosed with CAH with hyperandrogenism and severe salt-wasting shortly after
birth. However, the current steroid profile show complete adrenal insufficiency including
low production of pregnenolone, dehydroepiandrosterone (DHEA) and DHEA sulfate
(DHEA-S), without signs of overtreatment with steroids.
Conclusion: To the best of our knowledge, this is the first description of autoimmune
adrenalitis in a patient with 3βHSD2 deficiency and suggests a possible association
between AAD and inborn errors of the steroidogenesis.
Keywords: adrenal insufficiency, congenital adrenal hyperplasia, 3β-hydroxysteroid dehydrogenase type 2
deficiency, autoimmune adrenalitis, autoimmune Addison’s disease
INTRODUCTION
3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) catalyzes the conversion of 15-steroids into
14-steroids (Figure 1). Deficiency of 3βHSD2 causes a rare autosomal recessive form of congenital
adrenal hyperplasia (CAH) characterized by high levels of pregnenolone, 17-hydroxypregnenolone,
dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), and androstenediol, and lack of
cortisol, aldosterone, and androstenedione (1). There are two isozymes of 3βHSD encoded by
HSD3B1 andHSD3B2. 3βHSD2 is expressed in the gonads and the adrenal cortex, whereas 3βHSD1
is expressed in peripheral tissues, converting circulating DHEA to testosterone (1). 3βHSD2
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FIGURE 1 | Steroidogenesis in the adrenal cortex. Cholesterol is converted to aldosterone, cortisol, and androgens through different pathways that require specific
enzymes [cholesterol side-chain cleavage enzyme (CYP11A), 17α-hydroxylase (CYP17), 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2), 21-hydroxylase (CYP21),
11β-hydroxylase (CYP11B1), and aldosterone synthase (CYP11B2)]. Androstenedione and testosterone are further converted to dihydrotestosterone (DHT) and
estrogens in peripheral tissue.
FIGURE 2 | Levels of circulating 21OH autoantibodies in the patient (P1) and steroid profiling. (A) Using radioimmunoprecipitation assay, levels of 21OH
autoantibodies (blue) were measured in serum samples taken at different time points from 1996 to 2013. The cut-off value (red) was set to obtain the maximal
accuracy as calculated by an interlaboratory study (6). (B) Using ELISA, levels of pregnenolone, DHEA, and DHEA-S were measured in serum samples from the
patient (P1, blue) taken from different time points from 1996 to 2013. Normal adult values (green) are based on established reference values from the textbook
“Gynecologic Endocrinology” (pregnenolone) (7), hormone laboratory at Oslo University Hospital (DHEA) (https://ehandboken.ous-hf.no/api/File/GetFile?entityId=
105475) and hormone laboratory at Haukeland University Hospital (DHEA-S) (https://analyseoversikten.no/analyse/14). The average value of AAD patients (yellow) is
measured from serum samples of patients included in our biobank.
deficiency can therefore cause relatively high levels of
testosterone in females, whereas it cannot compensate for
the absence of adrenal and gonadal synthesis of testosterone
in males. This causes ambiguous genitalia in males, whereas
female newborns exhibit mild virilization or normal sexual
differentiation, and may remain undiagnosed until a salt-wasting
crisis occurs (1–3).
Adrenal insufficiency can also be due to autoimmune
adrenalitis, or autoimmune Addison’s disease (AAD),
characterized by an immunological attack of the adrenal
cortex leading to decreased production of cortisol and
aldosterone (4). The self-antigen 21-hydroxylase (21OH) is
the dominant target of adrenal autoantibodies and autoreactive
T cells (4). Therefore, autoantibodies against 21OH and
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low serum cortisol levels are important diagnostic markers
for AAD.
To the best of our knowledge, we here report the first patient
affected by both inborn 3βHSD2 deficiency and acquired AAD.
CASE REPORT
A whole-exome sequencing study involving 142 AAD patients
(5) revealed a patient with a rare homozygous mutation
in exon 2 of HSD3B2 [frequency ∼0.00003 in the Genome
Aggregation Database (gnomAD)] at nucleotide position
15 (NM_000198.3:c.15C>A), resulting in the exchange of
the cysteine codon to a premature stop codon (p.Cys5Ter).
Subsequent screening of the Norwegian Addison Registry
identified the patient harboring the mutation, a 55-year-
old female with AAD, premature ovarian insufficiency and
vitamin B12 deficiency, accompanied by 21OH- and parietal
cell autoantibodies (Figure 2A). Notably, she did not carry
any of the major histocompatibility complex (MHC) alleles
conferring high risk to develop AAD (4). She tested negative
for other autoantibodies such as anti-thyroid peroxidase, and
had normal levels of thyroid stimulating hormone (0.40–
4.50 mIU/L). Scrutiny of early medical records showed that
TABLE 1 | Steroid profile of the patient.

























Overview of the levels of 24 analytes in a fasting serum sample from the patient, including
the Lower Limit of Quantification Levels (LLoQ) for each analyte. The analysis was

























































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Endocrinology | www.frontiersin.org 3 September 2019 | Volume 10 | Article 648
Aslaksen et al. CAH and Autoimmune Adrenalitis Coexisting
she exhibited hyperpigmentation of genitalia and clitoris
hypertrophy already at birth. One week of age, she started
to vomit and developed hyponatremia (127 mmol/L) and
hyperkalemia (6.1 mmol/L). Elevated levels of 17-ketosteroids
were detected. She was therefore diagnosed with CAH
and supplemented with cortisone acetate and eventually
fludrocortisone. Her sister had also been diagnosed with
CAH, but unfortunately died in an adrenal crisis at 2 years
of age.
Given these conflicting findings, computer tomography
(CT) and magnetic resonance (MR) scans, taken from age 43
to 51, were re-evaluated and the adrenals were found to be
in the lower range of normal thickness 2–3mm, indicating
adrenocortical atrophy rather than hyperplasia as would be
expected in case of isolated CAH. We then obtained a steroid
profile by liquid chromatography tandem mass spectroscopy
(LC-MS/MS) of a serum sample taken after an overnight
medication fast (Table 1). Levels of all mineralocorticoids,
and most glucocorticoids and androgens were below the
detection limit, except for tetrahydrocortisol (0.308 nmol/L),
5α-tetrahydrocortisol (0.187 nmol/L), and testosterone
(0.066 nmol/L). Total pregnenolone, DHEA and DHEA-S
levels were measured by enzyme-linked immunosorbent
assay (ELISA) from previously collected serum samples
spanning the years 1996–2013 (Figure 2B). Normal levels of
pregnenolone and DHEA were found in samples from the
first 2 years, but then levels decreased toward the subnormal
levels generally seen in AAD patients. DHEA-S was also
below the normal range, typical of AAD patients, at all time
points. ACTH was measured at several time points, revealing
elevated levels on multiple occasions. The highest levels were
observed in 2011 at 130 pmol/L (normal range 2.0–11.6
pmol/L). Importantly, we detected no subsequent increase in
pregnenolone, DHEA, and DHEA-S in spite of elevated ACTH
levels (Figure 2B).
She is currently, at age 57, treated with 20mg hydrocortisone
(PlenadrenTM) and 100 µg fludrocortisone, and does not have
suppressed ACTH-values.
DISCUSSION
This is the first report of a patient with primary adrenal
insufficiency due to both 3βHSD2 deficiency and AAD. At
inclusion in the national Addison registry, she was classified
as having AAD with vitamin B12 deficiency, and 21OH-
and parietal cell autoantibodies. However, genetic screening
and scrutiny of old records revealed a rare form of CAH
due to a stop-gain mutation in HSD3B2. The presence of
small sized adrenal glands instead of hyperplastic glands,
normally seen in CAH, and no overproduction of ∆5-steroids
following elevated ACTH levels, suggest that the adrenal
cortex is not functioning. Presence of tetrahydrocortisol
and 5α-tetrahydrocortisol is consistent with her ongoing
replacement therapy which includes hydrocortisone. The
low, but detectable, level of testosterone may be due to
conversion of DHEA by 3βHSD1 in the periphery. Previously
measureable pregnenolone levels suggest that the autoimmune
destruction of the adrenal cortex commenced sometimes in
the 1990-ties.
According to literature, we could only find one reported
case of CAH occurring together with complete adrenal cortex
insufficiency suspected to be autoimmune adrenalitis. This
patient, however, had neither 21OH autoantibodies, nor MHC
risk alleles, but was positive for autoantibodies against 17α-
hydroxylase (8). Therefore, we speculate there might be other
rare unreported cases of autoimmune adrenalitis due to early
diagnosis of CAH, masking the clinical symptoms of AAD.
Interestingly, several other AAD patients included in our exome
sequencing analysis carry rare heterozygous non-synonymous
variants in HSD3B2 (Table 2). Although it appears that family
members of CAH patients, carrying heterozygous HSD3B2
mutations, maintain normal 3βHSD2 activity in vivo (14), genetic
variations in HSD3B2 are associated with other conditions such
as idiopathic hypospadias and prostate cancer (15, 16). Therefore,
both subtle molecular abnormalities and deleterious mutations
in HSD3B2 could have biological consequences, and may play a
role in the pathogenesis of the immune-mediated adrenocortical
destruction in AAD.
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